Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods – 11 March 2022

Overview

The Therapeutic Goods Act 1989 was enacted to provide a regulatory framework for the manufacture, importation, supply, and advertising of therapeutic goods in Australia. The Act was introduced to address the need for a comprehensive regulatory system that ensures the safety, quality, and efficacy of therapeutic goods available to the public. The Therapeutic Goods Administration (TGA), operating under the auspices of the Department of Health, is the body responsible for administering the Act. The policy objective is to protect public health by ensuring that therapeutic goods meet the necessary standards for safety, quality, and efficacy. On 11 March 2022, Katherine Clark, Delegate of the Secretary of the Department of Health, published details of licences granted to various entities for the manufacture of therapeutic goods. This publication is in accordance with Section 38 of the Therapeutic Goods Act 1989, ensuring transparency and accountability in the licensing process. The published list includes companies such as Pfizer Australia Pty Ltd, OFFCO Pty Ltd T/A Blue Dog Agriculture, Cannoperations Pty Ltd, Rapid Growth Pty Ltd T/a Pure Cannabis Australia, and Australia GMP Biopharmaceuticals Pty Ltd, each granted specific licences to manufacture therapeutic goods. This action reinforces the TGA's commitment to overseeing the manufacture of therapeutic goods to safeguard public health.

Scope and Application

The Therapeutic Goods Act 1989 pertains to the regulation of therapeutic goods in Australia, which includes products such as medicines, medical devices, blood, and tissues. This Act applies to a wide range of entities including manufacturers, importers, sponsors, and suppliers of therapeutic goods. It covers all therapeutic goods intended for use in Australia, encompassing both prescription and non-prescription medications, medical devices, and other regulated products. The Act's jurisdiction extends throughout the Commonwealth of Australia, thereby applying to all states and territories. Certain goods, such as certain blood products and tissues, may be exempt from some requirements under specific conditions. The scope of the Act can be further extended or specified through subordinate legislation, such as regulations and guidelines issued by the Therapeutic Goods Administration. These additional instruments help to detail specific standards, compliance measures, and enforcement mechanisms to ensure the safety, quality, and efficacy of therapeutic goods available in the Australian market.

Key Provisions

The Therapeutic Goods Act 1989 outlines several key provisions that are crucial for the regulation of therapeutic goods in Australia. Section 38 of the Act allows the Secretary to grant a licence to manufacture therapeutic goods, which is pivotal for companies involved in the production of such goods. This section provides the legal framework for companies to legally manufacture and supply therapeutic goods, ensuring they meet the required standards of quality and safety. The publication of the list of manufacturers granted such licences (Section 38) ensures transparency and allows stakeholders to verify the legitimacy of the therapeutic goods market. Entities granted a licence under Section 38 of the Therapeutic Goods Act 1989 must adhere to specific obligations and requirements. These include maintaining proper manufacturing practices, ensuring the quality and safety of the therapeutic goods produced, and complying with any conditions imposed by the Secretary on the licence. Manufacturers must also conduct regular inspections and audits to demonstrate compliance with the Act’s requirements, ensuring the therapeutic goods they produce meet the necessary standards. The Therapeutic Goods Act 1989 also establishes various offences, penalties, and consequences for breaches of the Act. Companies that fail to comply with the requirements of their licence or any conditions imposed can face significant penalties. For instance, a company that violates the Act may be subject to fines, imprisonment, or both, depending on the severity of the breach. The maximum penalties for breaches can vary, but they are designed to ensure that manufacturers take their obligations seriously and prioritise the safety and quality of the therapeutic goods they produce. Additionally, the Act allows for the imposition of civil penalties for breaches, which can include substantial fines. For criminal offences, the penalties can be even more severe, with imprisonment terms that may extend up to several years, depending on the nature and impact of the breach. These provisions serve as a deterrent to non-compliance and ensure that manufacturers are held accountable for any failures to meet the standards set out in the Act. This comprehensive regulatory framework helps protect public health by ensuring that therapeutic goods are safe, of high quality, and manufactured under stringent conditions.